Symptoms of parkinsonism and dementia frequently occur together, raising the question as to whether Alzheimer's disease (AD) and Parkinson's disease (PD) are two ends of a spectrum or unrelated entities that occur together by chance. The more recently recognized Lewy body disease (LBD), as a presumptive third entity, may also produce a clinical and pathological syndrome that can resemble either PD or AD, further complicating definition of the relationship between the disease processes. It is unknown whether LBD is simply an overlap syndrome between AD and PD, a variant of either AD or PD, or a distinct entity with it's own pathogenesis. The purpose of this investigation will be to use quantitative morphometry to study the neuropathological features in post mortem brains of patients with parkinsonism and dementia to determine whether there are quantitative pathologic features that separate LBD from AD and from PD. The principal investigator will obtain quantitative estimates of neuronal loss amyloid deposition, neurofribrillary tangles, neuritic degeneration and Lewy bodies in nine brain regions. We will then determine whether specific clusters of these features can be identified that distinguish the disease processes(es) of PD, AD and LBD as a spectrum or as two or three discrete conditions. The availability of brain tissue from patients with autosomal dominantly inherited forms of AD will also enable the PI to scrutinize the value of the clinical semiology and pathologic findings in cases of parkinsonism and dementia where specific etiologies have been identified.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29AG013623-04
Application #
2517042
Study Section
Neurology A Study Section (NEUA)
Project Start
1995-09-01
Project End
2000-08-31
Budget Start
1997-09-01
Budget End
1998-08-31
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Allegheny University of Health Sciences
Department
Neurology
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19129
Ishii, K; Lippa, C; Tomiyama, T et al. (2001) Distinguishable effects of presenilin-1 and APP717 mutations on amyloid plaque deposition. Neurobiol Aging 22:367-76
Lippa, C F; Swearer, J M; Kane, K J et al. (2000) Familial Alzheimer's disease: site of mutation influences clinical phenotype. Ann Neurol 48:376-9
Lippa, C F (1999) Familial Alzheimer's disease: genetic influences on the disease process (Review). Int J Mol Med 4:529-36
Lippa, C F; Schmidt, M L; Lee, V M et al. (1999) Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol 45:353-7
Nee, L E; Lippa, C F (1999) Alzheimer's disease in 22 twin pairs--13-year follow-up: hormonal, infectious and traumatic factors. Dement Geriatr Cogn Disord 10:148-51
Lippa, C F; Smith, T W; Perry, E (1999) Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology. J Neural Transm 106:525-35
Lippa, C F; Johnson, R; Smith, T W (1998) The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer's disease. Ann Neurol 43:102-6
Lippa, C F; Fujiwara, H; Mann, D M et al. (1998) Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153:1365-70
Lippa, C F; Nee, L E; Mori, H et al. (1998) Abeta-42 deposition precedes other changes in PS-1 Alzheimer's disease. Lancet 352:1117-8
Lippa, C F; Smith, T W; Saunders, A M et al. (1997) Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology 48:515-9

Showing the most recent 10 out of 11 publications